OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and…
| Price | $4.05 |
|---|---|
| Market cap | $130.78M |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Exchange | NASDAQ |
| 52-week range | 2.42-8.51 |
| Beta | 1.8 |
Explore IMDX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.